BerGenBio

Selective AXL inhibitors

Home  /  Investors

Investors

Quarterly Reports

Q1 2020 Report

Tuesday, 19 MayOnline

The webcast will be streamed LIVE and the recording will be available after LIVE session is finished.

Link to live webcast

Corporate Presentation

SACHS Digital Novel Coronavirus Investment Forum 9 July 2020

9 July 2020

Read More

Share price

BerGenBio ASA

BGBIO (Norway: Oslo)

Share Price Chart

News

Latest News

BERGENBIO ASA: Invitation to second quarter 2020 results webcast presentation

UPDATE ON BEMCENTINIB’S INVOLVEMENT IN POTENTIAL TREATMENT OF COVID-19 PANDEMIC

BERGENBIO ANNOUNCES FIRST PATIENT DOSED IN RECURRENT GLIOBLASTOMA INVESTIGATOR SPONSORED PHASE I/II STUDY ASSESSING SELECTIVE AXL INHIBITOR BEMCENTINIB

More News

Scientific Presentations

Next Gen Immuno-Oncology Congress 25 June 2020

25 June 2020

Read More

Annual Report 2019

BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.

Our annual report

Events

Upcoming Events

Extraordinary General Meeting

BERGENBIO ASA: Invitation to first quarter 2020 results webcast presentation

ACCORD – BerGenBio’s bemcentinib selected for fast-tracked UK Government study

BERGENBIO TO PRESENT AT THE UPCOMING 2020 SOLEBURY TROUT VIRTUAL INVESTOR CONFERENCE

Fourth quarter and full year 2019 results presentation and webcast

More Events